Tweedy Browne Co LLC Sells 358,589 Shares of Envista Holdings Co. (NYSE:NVST)

Tweedy Browne Co LLC reduced its stake in Envista Holdings Co. (NYSE:NVST) by 19.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,528,831 shares of the company’s stock after selling 358,589 shares during the period. Envista makes up about 2.0% of Tweedy Browne Co LLC’s holdings, making the stock its 12th largest holding. Tweedy Browne Co LLC’s holdings in Envista were worth $29,491,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. Amalgamated Bank boosted its stake in Envista by 0.7% in the 4th quarter. Amalgamated Bank now owns 80,380 shares of the company’s stock worth $1,551,000 after purchasing an additional 523 shares during the period. GAMMA Investing LLC boosted its position in shares of Envista by 30.5% in the fourth quarter. GAMMA Investing LLC now owns 2,304 shares of the company’s stock valued at $44,000 after acquiring an additional 538 shares during the period. M&T Bank Corp grew its stake in Envista by 4.2% during the fourth quarter. M&T Bank Corp now owns 16,621 shares of the company’s stock valued at $320,000 after acquiring an additional 676 shares in the last quarter. Assetmark Inc. increased its holdings in Envista by 2.5% during the 4th quarter. Assetmark Inc. now owns 39,624 shares of the company’s stock worth $764,000 after acquiring an additional 983 shares during the period. Finally, Xponance Inc. lifted its stake in Envista by 5.8% in the 4th quarter. Xponance Inc. now owns 19,726 shares of the company’s stock worth $381,000 after purchasing an additional 1,077 shares in the last quarter.

Envista Price Performance

Shares of Envista stock opened at $17.31 on Tuesday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.76 and a current ratio of 2.04. Envista Holdings Co. has a 52-week low of $15.15 and a 52-week high of $23.00. The company has a fifty day moving average of $19.54 and a 200-day moving average of $19.60. The stock has a market capitalization of $2.98 billion, a price-to-earnings ratio of -2.67, a price-to-earnings-growth ratio of 1.27 and a beta of 1.33.

Envista (NYSE:NVST) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.23 by $0.01. Envista had a negative net margin of 44.56% and a positive return on equity of 3.86%. Equities research analysts expect that Envista Holdings Co. will post 1 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. Needham & Company LLC restated a “hold” rating on shares of Envista in a research report on Thursday, March 6th. Mizuho assumed coverage on Envista in a research note on Wednesday, December 4th. They issued an “underperform” rating and a $20.00 target price on the stock. Piper Sandler raised their price target on Envista from $17.00 to $18.00 and gave the company a “neutral” rating in a report on Monday, February 3rd. Wells Fargo & Company set a $19.00 price objective on Envista in a report on Saturday, March 8th. Finally, JPMorgan Chase & Co. lowered their target price on shares of Envista from $20.00 to $19.00 and set a “neutral” rating on the stock in a research note on Thursday, March 6th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $20.18.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.